March 2026
Neuroplasticity
What March 2026's 11 new studies found, synthesized from the papers below. All Neuroplasticity research →
The synthesis
Synthesized from 11 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Neuroplasticity, neural plasticity, brain plasticity, synaptic plasticity, neurogenesis, then ranked by relevance.
Research in March 2026 consistently demonstrates that psychedelic compounds such as psilocin, MDMA, and oxa-noribogaine enhance neuroplasticity at the cellular and synaptic level in both human stem-cell-derived neurons and animal models. The evidence is robust across multiple studies, but is largely preclinical, with limited clinical translation and small sample sizes in human surveys.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Reshaping human neurons. 2026 | in vitro experimental | Supports | Psilocin increased structural complexity and synaptic connections in human neurons. | |
| Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC 2026 | RCT (animal model) | Supports | Oxa-noribogaine reduced alcohol drinking and relapse, associated with lasting glutamatergic and neurotrophic changes in cortico-striatal circuits. | |
| Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. 2026 | in vitro experimental | Supports | Psilocin enhanced neuronal complexity, synaptic protein expression, and network activity via 5-HT2A receptor-mediated BDNF increase. | |
| Distinct Molecular Responses to Ketamine and Imipramine in Cortical and Striatal Regions Following Acute Swim Stress 2026 | RCT (animal model) | Mixed | Ketamine and imipramine both facilitated active coping but via distinct molecular programs; ketamine preserved stress-evoked neuronal activation while imipramine dampened it. | |
| Integrated 5-HT 2A –TrkB and G protein signaling in serotonergic psychedelic responses 2026 | in vitro experimental | Supports | Serotonergic psychedelics induced dendritogenesis and synaptogenesis via 5-HT2A and TrkB signaling, with ligand-specific differences. | |
| Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy 2026 | review | Supports | Tabernanthalog (TBG) shows efficacy in reversing cognitive deficits and pain, with a multi-target profile beyond 5-HT2A agonism. | |
| Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil. 2026 | cross-sectional survey | 28 | Unclear | Athletes showed openness to psychedelic therapies but had low awareness and misconceptions; no direct neuroplasticity measures were reported. |
| Serotonergic modulation of excitatory synapse development and plasticity 2026 | review | Supports | Serotonin and psychedelics modulate excitatory synapse plasticity through 5-HT receptor signaling, affecting dendritic spine structure and function. | |
| MDMA enhances prefrontal plasticity and representational drift during fear extinction 2026 | RCT (animal model) | Supports | MDMA increased spine density and spinogenesis in prefrontal cortex and accelerated representational drift during fear extinction. | |
| Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors 2026 | RCT (animal model with conditional knockout) | Supports | Psychedelics induced synaptic enhancement in retrosplenial cortex via presynaptic 5-HT2A receptors, suggesting broader therapeutic utility. | |
| Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators. 2026 | review | Supports | Psychedelics, NMDA antagonists, and neuropeptides modulate synaptic transmission, dendritic remodeling, and gene expression linked to neuroplasticity. |
Psilocin increased structural complexity and synaptic connections in human neurons.
in vitro experimental
Oxa-noribogaine reduced alcohol drinking and relapse, associated with lasting glutamatergic and neurotrophic changes in cortico-striatal circuits.
RCT (animal model)
Psilocin enhanced neuronal complexity, synaptic protein expression, and network activity via 5-HT2A receptor-mediated BDNF increase.
in vitro experimental
Ketamine and imipramine both facilitated active coping but via distinct molecular programs; ketamine preserved stress-evoked neuronal activation while imipramine dampened it.
RCT (animal model)
Serotonergic psychedelics induced dendritogenesis and synaptogenesis via 5-HT2A and TrkB signaling, with ligand-specific differences.
in vitro experimental
Tabernanthalog (TBG) shows efficacy in reversing cognitive deficits and pain, with a multi-target profile beyond 5-HT2A agonism.
review
Athletes showed openness to psychedelic therapies but had low awareness and misconceptions; no direct neuroplasticity measures were reported.
cross-sectional survey Sample size: 28
Serotonin and psychedelics modulate excitatory synapse plasticity through 5-HT receptor signaling, affecting dendritic spine structure and function.
review
MDMA increased spine density and spinogenesis in prefrontal cortex and accelerated representational drift during fear extinction.
RCT (animal model)
Psychedelics induced synaptic enhancement in retrosplenial cortex via presynaptic 5-HT2A receptors, suggesting broader therapeutic utility.
RCT (animal model with conditional knockout)
Psychedelics, NMDA antagonists, and neuropeptides modulate synaptic transmission, dendritic remodeling, and gene expression linked to neuroplasticity.
review
Points of agreement
- Psychedelics (psilocin, MDMA, ibogaine derivatives) consistently enhance structural and functional neuroplasticity in preclinical models.
- 5-HT2A receptor signaling is a key mediator, but alternative pathways (e.g., presynaptic receptors, TrkB) also contribute.
- Neuroplastic changes are associated with behavioral improvements in addiction, fear extinction, and cognitive function.
Conflicts
- One study (28718) found that ketamine and imipramine produce similar behavioral outcomes via distinct molecular mechanisms, indicating that not all plasticity-enhancing drugs act through the same pathways.
- The cross-sectional survey (27904) found low awareness and misconceptions about psychedelics among athletes, contrasting with the positive preclinical evidence.
Gaps
- No large-scale human clinical trials directly measuring neuroplasticity outcomes in March 2026.
- Durability of neuroplastic changes beyond acute exposure is not well-characterized.
- Effects in diverse human populations (e.g., clinical patients, different age groups) are lacking.
- Potential maladaptive plasticity or long-term safety risks are not thoroughly addressed.